Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
acetylsalicyclic acid · 1 trial · 2 indications
The primary endpoint is the first occurrence of any of the following events: * Cardiovascular death (any death with a clear cardiovascular or unknown cause), * Myocardial Infarction (diagnosis of new Myocardial Infarction (MI) - nonfatal or fatal) * Stroke (presence of a new focal neurologic deficit thought to be vascular in origin, with signs or symptoms lasting more than 24 hours - nonfatal or fatal) reported between the randomization and Day 30 (inclusive), and validated by the blinded Event Adjudication Committee (EAC).
| Arm | Type | Description |
|---|---|---|
| Clopidogrel high dose treatment regimen + ASA high dose | EXPERIMENTAL | - |
| Clopidogrel high dose treatment regimen + ASA low dose | EXPERIMENTAL | - |
| Clopidogrel standard treatment regimen + ASA high dose | ACTIVE_COMPARATOR | - |
| Clopidogrel standard treatment regimen + ASA low dose | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Clopidogrel | DRUG | oral administration |
| acetylsalicyclic acid (ASA) | DRUG | oral administration |
Inclusion Criteria: * Diagnosed with acute coronary disease with clinical symptoms and at least electrocardiogram changes or cardiac enzymes elevated Exclusion Criteria: * Use of anticoagulants within 10 days with an international normalized ratio (INR) \> 1.5 or planned use during the hospitalis...
Acetylsalicylic acid is a small molecule being studied for use in Acute Coronary Disease, including unstable angina. It is currently in Phase 3 clinical development as an investigational therapy for this cardiovascular condition.
Sanofi (ticker: SNY) is the developer of acetylsalicylic acid. The company is conducting clinical research on this small molecule for the treatment of Acute Coronary Disease.
Acetylsalicylic acid is in Phase 3 clinical development. It is an investigational drug for Acute Coronary Disease and has not been approved by regulatory authorities for this indication.
Acetylsalicylic acid has one completed Phase 3 trial, NCT00335452, titled "Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent EveNTs/Optimal Antiplatelet Strategy for InterventionS." This randomized, double-blind, active-controlled study enrolled 25,086 participants with Acute Coronary Disease or unstable angina.
Acetylsalicylic acid is the chemical name for aspirin. In the context of this clinical trial, it is being evaluated as an antiplatelet agent for patients with Acute Coronary Disease.